InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
2.080
+0.040 (1.96%)
Nov 21, 2024, 11:39 AM EST - Market open
InflaRx Employees
InflaRx had 62 employees as of December 31, 2023. The number of employees increased by 18 or 40.41% compared to the previous year.
Employees
62
Change (1Y)
18
Growth (1Y)
40.41%
Revenue / Employee
$3,021
Profits / Employee
-$1,019,980
Market Cap
122.48M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Seres Therapeutics | 233 |
TELA Bio | 227 |
Century Therapeutics | 165 |
Rani Therapeutics Holdings | 140 |
Adlai Nortye | 127 |
Milestone Pharmaceuticals | 47 |
Journey Medical | 41 |
Fennec Pharmaceuticals | 29 |
IFRX News
- 6 days ago - InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome - GlobeNewsWire
- 13 days ago - InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress - GlobeNewsWire
- 2 months ago - InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases - GlobeNewsWire
- 3 months ago - InflaRx Announces Participation in September Investor Events - GlobeNewsWire
- 3 months ago - InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - InflaRx to Report Second Quarter 2024 Results on August 8, 2024 - GlobeNewsWire
- 5 months ago - InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS) - GlobeNewsWire